CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $18.09M, lower than 95% of all stocks globally
- PositionReturn on equity is -228.2%, lower than 95% of its Biotechnology peers (median -24.5%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.77BUSDvs all stocks (USD)
Revenue (TTM)
18.09MUSDvs all stocks (USD)
Beta
0.9030xvs all stocks
52-Week Change
177.59%vs all stocks
Market Capitalization
2.77BUSDvs all stocks (USD)
Enterprise Value
2.50BUSDvs all stocks (USD)
Forward P/E
-13.95xvs Biotechnology peers
Price to Book (MRQ)
16.99xvs Biotechnology peers
Enterprise to Revenue
138.04xvs Biotechnology peers
Enterprise to EBITDA
-14.28xvs Biotechnology peers
Gross Margin
93.85%vs Biotechnology peers
Operating Margin
-1321.11%vs Biotechnology peers
Return on Assets (TTM)
-16.98%vs Biotechnology peers
Return on Equity (TTM)
-228.24%vs Biotechnology peers
Revenue (TTM)
18.09MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.3020USDUpdated Jul 19, 2026Quarterly Revenue Growth
127.30%vs Biotechnology peers
Gross Profit (TTM)
-113.63MUSDvs all stocks (USD)
EBITDA (TTM)
-174.86MUSDvs all stocks (USD)
Net Income (TTM)
-208.87MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
127.31%vs Biotechnology peers
Operating Cash Flow (TTM)
-172.11MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-103.70MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
16.10MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
1.69MUSDFY2025 · Dec 31, 2025Gross Profit
14.41MUSDFY2025 · Dec 31, 2025Operating Income
-187.83MUSDvs all stocks (USD)
Pre-tax Income
-193.34MUSDFY2025 · Dec 31, 2025Income Tax Expense
5.63MUSDFY2025 · Dec 31, 2025Net Income
-198.97MUSDFY2025 · Dec 31, 2025EBIT
-131.35MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-148.72MUSDFY2025 · Dec 31, 2025Research & Development
140.67MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
65.34MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-5.68MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
16.97MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
61.99MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.46USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.46USDFY2025 · Dec 31, 2025Basic Shares Outstanding
57.50MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
57.50MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-198.97MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-136.55MUSDFY2025 · Dec 31, 2025Free Cash Flow
-136.99MUSDDerived from operating cash flow minus capital expenditure. This filing charges 14.76M of depreciation against 439K of capital expenditure, and its own free-cash-flow line reads -178.4M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
81.80MUSDFY2025 · Dec 31, 2025Interest Paid
25.07MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-198.97MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
14.76MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
1.59MUSDFY2025 · Dec 31, 2025Stock-based Compensation
17.68MUSDFY2025 · Dec 31, 2025Other Non-cash Items
39.66MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-8.60MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-2.67MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
0.00USDFY2025 · Dec 31, 2025Capital Expenditures
-439.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-658.38MUSDFY2025 · Dec 31, 2025Sale of Investments
337.19MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-321.62MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
391.90MUSDFY2025 · Dec 31, 2025Shares Outstanding
63.03MSharesUpdated Jul 19, 2026Float Shares
56.53MSharesUpdated Jul 19, 2026Shares Short
11.49MSharesUpdated Jul 19, 2026Short Ratio
3.85daysvs all stocks
Short % of Shares Outstanding
16.95%vs all stocks
% Held by Insiders
1.29%vs all stocks
% Held by Institutions
90.03%vs all stocks
Total Cash (MRQ)
586.55MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
9.30USDUpdated Jul 19, 2026Total Debt (MRQ)
545.66MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
3.65xvs Biotechnology peers
Current Ratio (MRQ)
10.40xvs Biotechnology peers
Book Value per Share (MRQ)
2.37USDUpdated Jul 19, 2026Total Assets
824.91MUSDvs all stocks (USD)
Total Current Assets
655.99MUSDFY2025 · Dec 31, 2025Total Liabilities
626.01MUSDFY2025 · Dec 31, 2025Total Non-current Assets
168.92MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
563.09MUSDFY2025 · Dec 31, 2025Total Current Liabilities
62.92MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
80.24MUSDFY2025 · Dec 31, 2025Other Short-term Investments
542.30MUSDFY2025 · Dec 31, 2025Accounts Receivable
5.86MUSDFY2025 · Dec 31, 2025Accounts Payable
5.17MUSDFY2025 · Dec 31, 2025Short-term Debt
3.86MUSDFY2025 · Dec 31, 2025Other Current Liabilities
23.46MUSDFY2025 · Dec 31, 2025Long-term Debt
59.53MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
495.59MUSDFY2025 · Dec 31, 2025Common Stock (Book)
3.69MUSDFY2025 · Dec 31, 2025Retained Earnings
-1.33BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
198.90MUSDvs all stocks (USD)
52-Week Low
8.73USDUpdated Jul 19, 202652-Week High
71.50USDUpdated Jul 19, 202652-Week Change
177.59%vs all stocks
Beta
0.9030xvs all stocks
50-Day MA
34.03USDUpdated Jul 19, 2026200-Day MA
29.45USDUpdated Jul 19, 2026Avg 10-Day Volume
1.31MSharesUpdated Jul 19, 2026Avg 30-Day Volume
2.49MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-3.57USDUpdated Jul 19, 2026Other Income / Expense
39.51MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -228.2%, lower than 95% of its Biotechnology peers (median -24.5%)Significant
Return on equity: -2.28Industry median: -0.25Industry P5: -1.55Peers compared: 197
Debt-to-equity is 3.65×, higher than 95% of its Biotechnology peers (median 0.1×)Significant
Debt-to-equity: 3.65Industry median: 0.10Industry P95: 2.96Peers compared: 197
Structural Tensions
Significant cash reserves alongside high leverageNotable
Cash (USD): 586,550,016Total Debt (USD): 545,656,000Debt-to-Equity: 3.65
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 10.40Altman Z-Score: 0.75
Financial Health
Altman Z-Score 0.75: distress zoneCritical
Altman Z-Score: 0.75
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $18.09M, lower than 95% of all stocks globallySignificant
Revenue (USD): 18,093,000Global P5: 30,274,777.221
Market cap is $2.77B, above the global median of $1.15BNotable
Market cap (USD): 2,767,360,494Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Vera Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Celldex Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Supernus Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Double Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Establishment Labs Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Joincare Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Trevi Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beam Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
CanSino Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ligachem Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking